CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · IEX Real-Time Price · USD
57.83
+2.76 (5.00%)
May 3, 2024, 9:39 AM EDT - Market open
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 407 employees on December 31, 2023. The number of employees decreased by 51 or -11.14% compared to the previous year.
Employees
407
Change (1Y)
-51
Growth (1Y)
-11.14%
Revenue / Employee
$912,054
Profits / Employee
-$377,420
Market Cap
4.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 407 | -51 | -11.14% |
Dec 31, 2022 | 458 | -15 | -3.17% |
Dec 31, 2021 | 473 | 63 | 15.37% |
Dec 31, 2020 | 410 | 106 | 34.87% |
Dec 31, 2019 | 304 | 116 | 61.70% |
Dec 31, 2018 | 188 | 61 | 48.03% |
Dec 31, 2017 | 127 | 34 | 36.56% |
Dec 31, 2016 | 93 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Bausch + Lomb | 13,300 |
Organon & Co. | 10,000 |
Perrigo Company | 9,140 |
Haemonetics | 3,034 |
Doximity | 977 |
BridgeBio Pharma | 550 |
Madrigal Pharmaceuticals | 376 |
Halozyme Therapeutics | 373 |
CRSP News
- 10 days ago - CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - GlobeNewsWire
- 4 weeks ago - CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - GlobeNewsWire
- 7 weeks ago - CRISPR Therapeutics Proposes New Appointment to the Board of Directors - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics Announces $280 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) - GlobeNewsWire